Post-Ischemic Stroke Clinical Trial
Official title:
This is a Multi-center, Double-blind, Three Arm, Parallel Group, Placebo-controlled, Randomized Study Designed to Evaluate the Efficacy, Safety and Tolerability of Dalfampridine.
The objective of this study is to determine the effect of two dose strengths of dalfampridine-Extended Release (ER) tablets, taken twice daily for 12 weeks, on stable walking deficits in subjects with post-ischemic stroke.
This was a randomized, placebo-controlled, three-arm, parallel-group study designed to evaluate the efficacy, safety, and tolerability of dalfampridine extended release (ER) tablets on chronic walking deficits in subjects with post-ischemic stroke. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02422940 -
Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine.
|
Phase 3 |